Activating GLP-1 receptors with liraglutide reduced pulmonary fibrosis in mice by disrupting the feedback loop between NLRP3 inflammasome activation, abnormal glycolysis, and pro-fibrotic gene expression in lung fibroblasts.
Novel NLRP3-glycolysis-lactylation axis identifiedGLP-1R activation breaks a feedback loop where inflammation drives abnormal sugar metabolism, producing lactate that epigenetically activates fibrosis genes — a mechanism not previously described in pulmonary fibrosis.
What the researchers found
Liraglutide (GLP-1R agonist) attenuated pulmonary inflammation and fibrosis in a silica-induced mouse model. Mechanistically, GLP-1R activation disrupted a newly identified feedback loop between the NLRP3 inflammasome and PFKFB3-driven glycolysis in lung fibroblasts.
Inhibiting either the NLRP3 inflammasome or glycolysis suppressed the other, decreasing lactate production. Excess lactate drives histone lactylation — a chemical modification that turns on pro-fibrotic genes. GLP-1R activation blocked this cascade by: (1) disrupting the NLRP3/glycolysis interaction, (2) preventing lactate-mediated histone lactylation, (3) protecting mitochondria from metabolic stress, and (4) suppressing p300-mediated histone lactylation even when lactate was added directly. GLP-1R activation also blocked macrophage-to-fibroblast activation signaling.
Why it matters
Pulmonary fibrosis currently has no effective treatment besides lung transplantation. Approved antifibrotic drugs (pirfenidone, nintedanib) only slow progression modestly. Discovering that GLP-1 receptor agonists — drugs already approved and widely used for diabetes — can target fibrosis through a novel metabolic-epigenetic mechanism opens a potentially rapid pathway to clinical testing for this devastating condition.
How the study worked
Researchers used a silica-induced pulmonary fibrosis mouse model (C57BL/6 mice) treated with liraglutide in vivo. In vitro experiments used primary lung fibroblasts stimulated with TGF-β1 combined with IL-1β. Cell metabolism assays measured glycolytic rate and mitochondrial respiration. RNA sequencing analyzed molecular mechanisms. ChIP-qPCR evaluated histone lactylation at promoters of pro-fibrotic genes. Additional pharmacological inhibitors (MCC950 for NLRP3, 3PO for PFKFB3) were used to dissect the pathway.
What this study cannot tell us
The study used a silica-induced fibrosis model in mice, which may not fully replicate human idiopathic pulmonary fibrosis. No human clinical data were presented. The specific liraglutide doses and treatment timing relative to fibrosis onset (prevention vs. treatment) need clarification. Long-term effects and potential for lung-specific delivery were not explored. The complex molecular pathway identified in cell culture may be more nuanced in vivo.
How to read the evidence
This is a comprehensive preclinical study combining in vivo mouse models with detailed in vitro mechanistic work and RNA sequencing. The evidence is strong for the preclinical stage but has not been validated in human patients.
When this study was published
Published in 2024, this study represents the latest research into GLP-1 receptor agonists for non-metabolic diseases, a rapidly expanding field.
The bigger picture
GLP-1 receptor agonists are increasingly being discovered to have benefits far beyond blood sugar control — in the heart, liver, kidneys, and now potentially the lungs. This study adds pulmonary fibrosis to the growing list of conditions where GLP-1R activation shows therapeutic promise. The novel mechanism involving histone lactylation (an epigenetic modification driven by metabolic changes) also advances our understanding of how metabolism and gene regulation interact in fibrotic disease.
Questions still open
- Would GLP-1 receptor agonists show antifibrotic effects in human pulmonary fibrosis patients?
- Is the NLRP3/glycolysis/lactylation pathway also active in idiopathic pulmonary fibrosis, or only in silica-induced fibrosis?
- Could combining GLP-1R agonists with existing antifibrotic drugs produce synergistic benefits?
Common questions
Could diabetes drugs like liraglutide help treat lung fibrosis?
What is histone lactylation and why does it matter for fibrosis?
Read the original research
GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation.
Journal of translational medicine, 22(1), 954
Citation
Liu, Chenyang; Zhang, Qun; Zhou, Hong; Jin, Linling; Liu, Chang; Yang, Mingxia; Zhao, Xinyun; Ding, Wenqiu; Xie, Weiping; Kong, Hui. (2024). GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation.. Journal of translational medicine, 22(1), 954. https://doi.org/10.1186/s12967-024-05753-z